Frankfurt - Delayed Quote • EUR BeiGene, Ltd. (49B.F) Follow Compare 16.80 +0.10 +(0.60%) At close: January 31 at 8:20:01 AM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 49B.F 1D 5D 7.69% 1M 27.27% 3M 15.07% 6M 54.13% YTD 27.27% 1Y 52.73% 5Y 61.54% All 52.04% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 49B.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value Exploring High Growth Tech Stocks in January 2025 When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)? BeiGene Stock Meets 80-Plus RS Rating Benchmark BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last? BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment BeiGene Secures FDA Approval for Stomach Cancer Drug TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy Exploring Three High Growth Tech Stocks In The United States